Windlas Biotech Limited (NSE:WINDLAS)

Market Cap	20.87B
Revenue (ttm)	7.95B
Net Income (ttm)	651.79M
Shares Out	20.90M
EPS (ttm)	30.76
PE Ratio	32.46
Forward PE	n/a
Dividend	5.80 (0.58%)
Ex-Dividend Date	Jul 21, 2025

Volume	57,506
Average Volume	104,657
Open	994.20
Previous Close	994.20
Day's Range	991.00 - 1,020.05
52-Week Range	665.10 - 1,198.25
Beta	0.28
RSI	53.33
Earnings Date	Aug 11, 2025

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophiliz...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,154
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WINDLAS

Financial Performance

In 2024, Windlas Biotech's revenue was 7.60 billion, an increase of 20.43% compared to the previous year's 6.31 billion. Earnings were 609.94 million, an increase of 4.82%.